Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.53 |
| ▸ | ARG2 | P78540 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 5/20 | 0.52 |
| ▸ | NOS1 | P29475 | 3/20 | 0.52 |
| ▸ | NOS3 | P29474 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | BHMT | Q93088 | 4/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2781165 | 1.00 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL27552293 | 1.00 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 | |
| Carbocysteine SCHEMBL9236855 | 0.86 | BHMT (0.59) | ARG1ARG2NOS2NOS1NOS3 | |
| Carbocysteine SCHEMBL6762355 | 0.86 | BHMT (0.59) | ARG1ARG2NOS2NOS1NOS3 | |
| Carbocysteine SCHEMBL69149 | 0.86 | BHMT (0.59) | ARG1ARG2NOS2NOS1NOS3 | |
| Carbocysteine SCHEMBL20854 | 0.86 | BHMT (0.59) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL18788686 | 0.86 | ARG1 (0.53) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL36934 | 0.85 | ARG1 (0.61) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL36935 | 0.85 | ARG1 (0.61) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL29378137 | 0.85 | ARG1 (0.61) | ARG1ARG2NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552839-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIROMETIX AG (CH) | 2026-02-17 | — | — | US | claimed |
| EP-4551948-A2 | COMPOSITIONS AND METHODS FOR POLYPEPTIDE ANALYSIS | Quantum-Si Incorporated (US) | 2025-05-14 | — | — | EP | claimed |
| CN-119998660-A | Compositions and methods for polypeptide analysis | 宽腾矽公司 | 2025-05-13 | — | — | CN | claimed |
| US-20240287143-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | Universität Zürich (CH) | 2024-08-29 | — | — | US | claimed |
| WO-2024031031-A2 | COMPOSITIONS AND METHODS FOR POLYPEPTIDE ANALYSIS | Quantum-Si Incorporated (US) | 2024-02-08 | — | — | WO | claimed |
| EP-4295866-A2 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | Virometix AG (CH) | 2023-12-27 | — | — | EP | claimed |
| EP-3638284-B1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | VIROMETIX AG (CH) | 2023-08-30 | — | — | EP | claimed |
| US-11680085-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIROMETIX AG (CH) | 2023-06-20 | — | — | US | claimed |
| US-20210101941-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | Universität Zürich (CH) | 2021-04-08 | — | — | US | claimed |
| EP-3638284-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | Virometix AG (CH) | 2020-04-22 | — | — | EP | claimed |
| CN-110891592-A | Cyclic peptides for protection against respiratory syncytial virus | 维罗米蒂克斯股份公司 | 2020-03-17 | — | — | CN | claimed |
| WO-2018229156-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | VIROMETIX AG (CH) | 2018-12-20 | — | — | WO | claimed |
| US-20260137767-A1 | LIPOPEPTIDE BUILDING BLOCKS AND SYNTHETIC VIRUS-LIKE PARTICLES | VIROMETIX AG (CH) | 2026-05-21 | — | — | US | disclosed |
| US-12552839-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIROMETIX AG (CH) | 2026-02-17 | — | — | US | disclosed |
| US-20260016481-A1 | POLYPEPTIDE SEQUENCING REAGENTS AND METHODS OF USE | Quantum-Si Incorporated (US) | 2026-01-15 | — | — | US | disclosed |
| US-12465633-B2 | Lipopeptide building blocks and synthetic virus-like particles | VIROMETIX AG (CH) | 2025-11-11 | — | — | US | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| EP-1085000-B1 | PROCESS FOR PRODUCING CARBOXYLIC ACID DERIVATIVE AND CONDENSING AGENT COMPRISING QUATERNARY AMMONIUM SALT | TOKUYAMA CORP (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-6458948-B1 | MIXING A QUATERNARY AMMONIUM SALT HAVING A PARTICULAR TRIAZINE RING IN THE MOLECULES THEREOF, A CARBOXYLIC ACID COMPOUND AND A COMPOUND HAVING A NUCLEOPHILIC FUNCTIONAL GROUP, TO CONDENSE THE CARBOXYLIC ACID WITH THE COMPOUND HAVING THE NUCLEOPHILIC | TOKUYAMA CORPORATION (JP) | 2002-10-01 | — | — | US | disclosed |
| EP-1085000-A1 | PROCESS FOR PRODUCING CARBOXYLIC ACID DERIVATIVE AND CONDENSING AGENT COMPRISING QUATERNARY AMMONIUM SALT | TOKUYAMA CORPORATION (JP) | 2001-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680085-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIP, LNPEP, CSTB | ARG1 806/4885ARG2 648/4885NOS2 3429/4885 |
| US-20260016481-A1 | POLYPEPTIDE SEQUENCING REAGENTS AND METHODS OF USE | ARGLU1, SPPL2B, QPCTL | ARG1 36/4885ARG2 104/4885NOS2 1797/4885 |
| US-20260137767-A1 | LIPOPEPTIDE BUILDING BLOCKS AND SYNTHETIC VIRUS-LIKE PARTICLES | VSIR, LRBA, CD74 | ARG1 537/4885ARG2 1831/4885NOS2 4265/4885 |
| US-12465633-B2 | Lipopeptide building blocks and synthetic virus-like particles | VSIR, CXCL10, SGTA | ARG1 1090/4885ARG2 2887/4885NOS2 4435/4885 |
| US-20240287143-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | VIP, QPCT, QPCTL | ARG1 251/4885ARG2 931/4885NOS2 2421/4885 |
| US-20210101941-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | QPCT, QPCTL, VIP | ARG1 399/4885ARG2 1038/4885NOS2 3189/4885 |
| US-12552839-B2 | Cyclic peptides for protection against respiratory syncytial virus | CTH, VIP, CXCL10 | ARG1 415/4885ARG2 741/4885NOS2 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.